Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646299 | 1.00 | MAPK14 (0.44) | MAPK14TRPA1METKDRLPAR2 | |
| SCHEMBL4762099 | 0.88 | MAPK14 (0.39) | MAPK14TRPA1LPAR2CYP1A2KDM4E | |
| SCHEMBL13646271 | 0.82 | MAPK14 (0.42) | MAPK14TRPA1LPAR2CYP1A2KDM4E | |
| SCHEMBL3876655 | 0.82 | MAPK14 (0.42) | MAPK14TRPA1LPAR2CYP1A2KDM4E | |
| SCHEMBL3865346 | 0.80 | MAPK14 (0.46) | MAPK14TRPA1METKDRCYP1A2 | |
| SCHEMBL13646288 | 0.80 | MAPK14 (0.46) | MAPK14TRPA1METKDRCYP1A2 | |
| SCHEMBL4019972 | 0.71 | MAPK14 (0.40) | MAPK14TRPA1METKDRLPAR2 | |
| SCHEMBL13764812 | 0.71 | MAPK14 (0.40) | MAPK14TRPA1METKDRLPAR2 | |
| SCHEMBL13646272 | 0.68 | SCN9A (0.34) | MAPK14TRPA1METLPAR2LMNA | |
| SCHEMBL3864520 | 0.68 | SCN9A (0.34) | MAPK14TRPA1METLPAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1919913-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007023110-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAPK14 36/4885TRPA1 4678/4885MET 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.